Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Carregando...
Citações na Scopus
317
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
TABERNERO, Josep
SHEN, Lin
OHTSU, Atsushi
SHAH, Manish A.
CHENG, Karen
SONG, Chunyan
WU, Haiyan
ENG-WONG, Jennifer
KIM, Katherine
Citação
LANCET ONCOLOGY, v.19, n.10, p.1372-1384, 2018
Resumo
Background Adding pertuzumab to trastuzumab and chemotherapy improves survival in HER2-positive early breast cancer and metastatic breast cancer. We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzuinab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer. Methods JACOB was a double-blind, placebo-controlled, randomised, multicentre, phase 3 trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer. Eligible patients had measurable or evaluable non-measurable disease at baseline, Eastern Cooperative Oncology Group performance status of 0 or 1, and baseline left ventricular ejection fraction of 55% or more. Patients at 197 oncology clinics (in 30 countries) were randomly assigned (1:1) to receive either pertuzumab (840 mg intravenously) or placebo every 3 weeks, with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks intravenously), plus chemotherapy (cispla tin 80 mg/m(2) every 3 weeks intravenously, oral capecitabine 1000 mg/m(2) twice a day [2000 mg/m(2) every 24 hi for 28 doses every 3 weeks, or 5-fluorouracil 800 mg/m(2) every 24 h intravenously [120 h continuous infusion] every 3 weeks). Randomisation was by a central permuted block randomisation scheme (block size of 4) with an interactive voice or web response system, stratified by geographical region, previous gastrectorny, and HER2 positivity. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with Clinicaltrials. gov, number NCT01774786 (ongoing, but closed to enrolment). Findings Between June 10, 2013, and Jan 12, 2016, of 3287 patients assessed, 780 eligible patients were randomly assigned to receive either pertuzumab plus trastuzumab and chemotherapy (pertuzumab group, n=388) or placebo plus trastuzumab and chemotherapy (control group, n=392). Median duration of follow-up was 24.4 months (95% CI 22.3-26.1) in the pertuzumab group and 25.0 months (22.3-28.9) in the control group. After 242 deaths in the pertuzumab group and 262 deaths in the control group (the study was not stopped at this point), overall survival was not significantly different between treatment groups (median overall survival 17.5 months ps% CI 16. 2-19.31in the pertuzumab group and 14.2 months [12.9-15.5] in the control group; hazard ratio 0.84 [95% CI 0. 71-1. 00]; p=0.057). Serious adverse events occurred in 175 (45%) of 385 patients in the pertuzumab group and 152 (39%) of 388 patients in the control group. Diarrhoea was the most common serious adverse event in both groups (17 [4%] patients in the pertuzumab group vs 20 [5%] patients in the control group). The most common grade 3-5 adverse events were neutropenia (116 [30%] patients in the pertuzumab group vs 108 [28%] patients in the control group), anaemia (56 [15%] vs 65 [17%]), and diarrhoea (51 [13%] vs 25 [6%]). Treatment-related deaths occurred in seven (2%) patients in the control group; no treatment-related deaths occurred in the pertuzumab group. Interpretation Adding pertuzumab to trastuzumab and chemotherapy did not significantly improve overall survival in patients with HER2-positive metastatic gastric or gastro-oesophageal junction cancer compared with placebo. Further studies are needed to identify improved first-line treatment options in these types of cancer and to identify patients with HER2-driven tumours who might benefit from dual HER2-targeted therapy.
Palavras-chave
Referências
- Bang YJ, 2010, LANCET, V376, P1302
- Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
- Cortes J, 2013, ANTI-CANCER DRUG, V24, P1084, DOI 10.1097/CAD.0000000000000016
- Genentech Inc. KADCYLA (ado-trastuzumab emtansine), PRESCRIBING INFORM
- GlaxoSmithKline. TYKERB (lapatinib), PRESCRIBING INFORM
- Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169
- Hecht JR, 2016, J CLIN ONCOL, V34, P443, DOI 10.1200/JCO.2015.62.6598
- Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x
- Ieni A, 2014, INT J MOL SCI, V15, P22331, DOI 10.3390/ijms151222331
- Kang YK, 2014, BRIT J CANCER, V111, P660, DOI 10.1038/bjc.2014.356
- Kirschbrown WP, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2564
- Lei YY, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1132-5
- National Comprehensive Cancer Network (NCCN), NCCN CLIN PRACT GUID
- Novartis Europharm Limited, ANN 1 SUMM PROD CHAR
- Ock CY, 2016, GASTRIC CANCER, V19, P421, DOI 10.1007/s10120-015-0504-1
- Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139
- Peng Z, 2015, CHINESE J CANCER RES, V27, P163, DOI 10.3978/j.issn.1000-9604.2014.12.09
- Roche Registration Ltd. Kadcyla (trastuzumab emtansine), ANN 1 SUMM PROD CHAR
- Ruschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198
- Shah MA, 2017, J CLIN ONCOL, V35, P2558, DOI 10.1200/JCO.2016.71.6852
- SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
- Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350
- Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513
- ter Veer E, 2018, INT J CANCER, V143, P438, DOI 10.1002/ijc.31325
- Thuss-Patience PC, 2017, LANCET ONCOL, V18, P640, DOI 10.1016/S1470-2045(17)30111-0
- von Minckwitz G, 2017, NEW ENGL J MED, V377, P122, DOI 10.1056/NEJMoa1703643
- WHO International Agency for Research on Cancer, CANC FACT SHEETS STO